Extract
The relationship between smoking status and total immunoglobulin levels in patients with COPD is not fully understood. Decreased immunoglobulin levels have been observed in patients with COPD [1–4], a disease largely attributed to current or former smoking, and cigarette smokers [5, 6]. These studies focused predominately on serum (systemic) or salivary (upper respiratory tract) immunoglobulins. Levels of immunoglobulins in induced sputum, a more direct measure of airway immunoglobulins, are less well studied. Given the vital role immunoglobulins perform in microbial defence and tissue homeostasis, we assessed airway immunoglobulins in induced sputum of smokers and patients with COPD.
Abstract
Current smoking status in subjects with mild to moderate COPD was associated with reduced total induced sputum IgM and IgG. This reduction in immunoglobulins was independent of inhaled corticosteroid use. https://bit.ly/2FtBg1t
Footnotes
This study is registered at clinicaltrials.gov with identifiers NCT01274507 and NCT03240315.
Conflict of interest: S.P. Cass has nothing to disclose.
Conflict of interest: Y. Yang has nothing to disclose.
Conflict of interest: J. Xiao has nothing to disclose.
Conflict of interest: J.J.C. McGrath has nothing to disclose.
Conflict of interest: M.F. Fantauzzi has nothing to disclose.
Conflict of interest: D. Thayaparan has nothing to disclose.
Conflict of interest: F. Wang has nothing to disclose.
Conflict of interest: Z. Liang has nothing to disclose.
Conflict of interest: F. Long has nothing to disclose.
Conflict of interest: C.S. Stevenson is an employee of Johnson & Johnson.
Conflict of interest: R. Chen has nothing to disclose.
Conflict of interest: M.R. Stampfli reports grants from Canadian Institutes of Health Research and RespiVert Ltd, part of Janssen Pharmaceuticals, during the conduct of the study; grants from RespiVert Ltd, part of Janssen Pharmaceuticals, personal fees from AstraZeneca and Boehringer Ingelheim, outside the submitted work.
Support statement: This study was supported in part by the Canadian Institutes of Health Research (PJT-159792), RespiVert Ltd, part of Janssen Pharmaceuticals, National Key R&D Program of China (2017YFC1310600), Guangzhou Healthcare Collaborative Innovation Major Project (201604020012) and Medical Scientific Research Foundation of Guangdong Province (C2017050). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received December 20, 2019.
- Accepted August 13, 2020.
- Copyright ©ERS 2021
LIBRARY USERS
Log in through your institution
Purchase access
